- ICH GCP
- US Clinical Trials Registry
- Clinical Trial NCT04099719
Geographical Information System (GIS) Mapping to Assess the Need for IEP Provision in Tayside
A GIS Mapping Exercise to Assess the Need for Injecting Equipment Provision (IEP) Services and Overdose Prevention Activities in Tayside.
Study Overview
Status
Conditions
Detailed Description
People who inject drugs (PWIDs) do so at significant risk to themselves due to transmission of blood borne viruses (BBV), injecting injuries, bacterial infections and drug related deaths.
NHS Tayside has a responsibility for improving the health of the population. PWIDs represent a particularly vulnerable group who experience significant health inequalities as well as stigmatisation and discriminatory attitudes.
Injecting Equipment Provision (IEP) services contribute to a reduction in BBV transmission through the provision of free sterile equipment for each injection. IEP services also provide advice on good injecting technique to avoid injecting injuries and bacterial infections. Crucially they can also provide "take home naloxone". Intramuscular injection of naloxone is a first aid emergency response for potentially fatal opiate overdoses and provides more time for emergency services to attend. Supplies of "take home naloxone" are made, along with training on overdose awareness, to those individuals at risk of opioid overdose in order to reduce the risk of fatality.
IEP services contribute to a reduction in drug related deaths by engaging with those thought to be most at risk, either through poly substance use or those who are not engaged with other services
The aim of this study is to review the current provision of IEP services provided across Tayside and consider to what extent they are contributing to keeping this vulnerable population safe. The study will look at the coverage provided by the current service and map this against the known harms e.g. drugs litter finds, incidences of non-fatal overdoses and drug related deaths. This mapping process will then allow recommendations to be made in a strategic way to advise future service delivery plans to ensure that services are delivered that are reachable to the communities that need these valuable services.
The protocol has been peer reviewed by the expert working group established to review the current provision of IEP and harm reduction and overdose awareness services across Tayside
Individual consent from patients will not be sought. The data provided by the databases will be retrospective 4 digit postcode data and will not include patient identifiable information. The data obtained will not be used in any way which may influence the care of the patient.
Data collection methods will not identify individual patients.
Researchers will be accessing information from databases which they have access to as part of their routine work. Information will remain anonymous and patient confidentiality will be upheld.
Separate consents will be sought to allow council colleagues to provide information on drug litter finds.
Anonymous 4 digit postcode data will be transferred onto Geographic Information System (GIS) maps to demonstrate coverage of services mapped against known harms (non-fatal overdoses, drug related deaths and drug litter finds). GIS maps do not identify individual postcodes.
The GIS maps will be used to identify gaps in the provision of services and provide an evidence base behind recommendations to improve service provision.
Study Type
Enrollment (Actual)
Contacts and Locations
Study Locations
-
-
Tayside
-
Dundee, Tayside, United Kingdom, DD3 8EA
- Directorate of Public Health
-
-
Participation Criteria
Eligibility Criteria
Ages Eligible for Study
Accepts Healthy Volunteers
Genders Eligible for Study
Sampling Method
Study Population
Description
Inclusion Criteria:
Anyone (>16 years old) registered with services providing drug treatment and harm reduction activities in Tayside Retrospective data from the identified databases which identifies 4 digit postcode unit of residence. All activity will be included regardless of patient characteristics.
Data will be gathered retrospectively from the past year.
Exclusion Criteria:
Data that does not identify 4 digit postcode unit of residence
Study Plan
How is the study designed?
Design Details
Cohorts and Interventions
Group / Cohort |
|---|
|
Anyone (>16 years old) registered with services providing drug
retrospective data, no intervention to be administered
|
What is the study measuring?
Primary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
|---|---|---|
|
GIS mapping of IEP and overdose prevention activity across Tayside
Time Frame: 1 year
|
number and 4 digit postcode location of individuals accessing IEP services, receiving Opiate Substitution Therapy from Community Pharmacy, Number and 4 digit postcode location of naloxone kits distributed, number and 4 digit postcode location of drug deaths, number and 4 digit postcode location of non fatal overdoses, number and location of drug litter finds.
|
1 year
|
Secondary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
|---|---|---|
|
Construct a GIS map of the coverage of each community pharmacy in Tayside for Opiate Substitution Therapy (OST) dispensing
Time Frame: 1 year
|
4 digit postcodes of OST prescriptions from Controlled Drug database for each community pharmacy
|
1 year
|
|
Construct a GIS map of the coverage of each IEP site in Tayside
Time Frame: 1 year
|
4 digit postcodes of those accessing IEP sites recorded on NEO database
|
1 year
|
|
Construct a GIS map of Drug litter finds e.g. discarded needles reported to council colleagues for safe disposal
Time Frame: 1 year
|
Postcode of locations of drug litter finds
|
1 year
|
|
Non-fatal overdoses mapped onto a HEAT map.
Time Frame: 1 year
|
4 digit postcode of patients experiencing Non-fatal overdoses (NFOD) from NFOD database
|
1 year
|
|
Drug deaths mapped onto a HEAT map
Time Frame: 1 year
|
4 digit postcode of those lost to Drug Deaths from Drug Death database
|
1 year
|
|
Take Home Naloxone supply data mapped
Time Frame: 1 year
|
4 digit postcode information for people supplied naloxone on naloxone database
|
1 year
|
Collaborators and Investigators
Sponsor
Investigators
- Principal Investigator: Sarah R Donaldson, MRPharmS, NHS Tayside
Study record dates
Study Major Dates
Study Start (ACTUAL)
Primary Completion (ACTUAL)
Study Completion (ACTUAL)
Study Registration Dates
First Submitted
First Submitted That Met QC Criteria
First Posted (ACTUAL)
Study Record Updates
Last Update Posted (ACTUAL)
Last Update Submitted That Met QC Criteria
Last Verified
More Information
Terms related to this study
Other Study ID Numbers
- 3-010-18
Drug and device information, study documents
Studies a U.S. FDA-regulated drug product
Studies a U.S. FDA-regulated device product
This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.
Clinical Trials on Drug Use
-
Chestnut Health SystemsNational Institute on Drug Abuse (NIDA)Active, not recruitingPolysubstance Drug Use (Indiscriminate Drug Use)United States
-
University of California, Los AngelesInstituto Nacional de Psiquiatría Dr. Ramón de la FuenteCompletedDrug Use | Harmful Use
-
University of California, Los AngelesCompleted
-
University of California, Los AngelesNational Institute on Drug Abuse (NIDA); Medical University of South Carolina; University of ArkansasActive, not recruitingDrug UseUnited States
-
Hamad Medical CorporationPrimary Health Care Corporation, QatarActive, not recruiting
-
PT. Kimia Farma (Persero) TbkPT Pharma Metric LabsCompleted
-
PT BernofarmPT Pharma Metric LabsCompleted
-
Ain Shams UniversityRecruiting
-
PT Kalbe Farma TbkPT Pharma Metric LabsCompleted
-
Assistance Publique Hopitaux De MarseilleUnknown